微信公众号
Entering Kaqiu
About Caltu
As an innovator in the field of precision medicine, Caltu Bio has built a "precision medical diagnosis and testing" technology ecosystem since its establishment in 2020. The company relies on five core platforms — conjugated antibody development platform, high-throughput monoclonal antibody engineering platform, multi-omics molecular diagnosis and epigenetic analysis platform, intelligent manufacturing platform for medical devices, and companion diagnostic target discovery system — forming a full industry value chain closed loop covering biomarker discovery, diagnostic reagent development, and therapeutic drug companion services.
In terms of R&D capability building, the company has a 5000㎡ R&D base, led by an interdisciplinary team with over 60% PhD/Master talents, focusing on continuous breakthroughs in the field of tumor precision diagnosis and treatment. Based on the independently developed liquid biopsy methylation marker capture technology and spatial multi-omics analysis system, two major product lines have been launched: the tissue origin diagnosis system can achieve 92.7% precise localization of unknown primary tumors, and the circulating tumor DNA ultra-early lung cancer screening program achieves >90% sensitivity and specificity detection. Based on this technology, the R&D team explores early signal detection of neurodegenerative diseases, contributing to Healthy China.
transformation of precision medical solutions.
As an innovation benchmark in the IVD industry, the company has built a product matrix covering all diagnostic scenarios: independently developed 10+ secondary antibody kits, innovative rapid immunohistochemistry detection system achieving 15-minute frozen section detection, fully automated multiplex immunohistochemistry staining instrument + AI-driven digital pathology analysis system, enabling single-slide multi-target simultaneous detection and multi-marker analysis. All these products have been introduced into top-tier domestic tertiary hospitals and leading medical testing centers in China.
In the field of companion diagnostics, strategic partnerships have been established with multiple leading pharmaceutical companies. Relying on the antibody development platform, they jointly develop high-sensitivity, high-specificity companion diagnostic test kits, providing key support for innovative drug development through precise biomarker detection, helping to realize the "personalized medication-companion diagnostics" closed-loop development model and accelerating the clinical application transformation of precision medical solutions.
Industry Deepening
Company Area
Self-developed Antibodies
Patent Authorization
Product Pipeline
Secondary Antibody Amplification System
Corporate Philosophy
Co-entrepreneurship, shared success, and mutual sharing
Innovation leads technology
Innovation leads technology, adding glory to China's medical manufacturing.
Corporate Culture
Development History
Year 2020
Year 2021
Year 2022
Year 2023